Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary Sjögren’s syndrome in Lupus, the importance of this protein across a spectrum of autoimmune conditions is clear.
| Over 1,000,000 Patients Clinically Tested |
Patient autoimmune biology changes along the disease course… and so does their 14-3-3η biomarker levels
2015
Serum 14-3-3eta Are Elevated in Indigenous North Americans with Rheumatoid Arthritis and May Predict Imminent Synovitis in Their at-Risk First Degree Relatives
2016
A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia
Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
2018
The Diagnostic Value of 14-3-3η Protein Levels in Patients with Rheumatoid Arthritis
2020
Serum 14-3-3η Protein is Associated with Clinical and Serologic Features of Sjögren’s Syndrome in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Analysis
2016
Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis
2020
Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: prediction by serum biomarkers
2015
Serum 14-3-3η Level is Associated with Severity and Clinical Outcomes of Rheumatoid Arthritis, and its Pretreatment Level is Predictive of DAS28 Remission with Tocilizumab
2019
Decrease in 14-3-3η Protein Levels is Correlated with Improvement in Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib
2020
Correlation of Plasma 14-3-3η Levels with Disease Activity Measures in Methotrexate-Naïve RA Patients Treated with Upadacitinib Monotherapy in the Select-Early Phase 3 Study
Confidence with 14-3-3η
Biologically-Informed Autoimmune Clinical Assessment
| For an expanded list of 14-3-3η publications visit our publications page. |
| Test available at: |
